164 related articles for article (PubMed ID: 19671328)
1. [Efficacy of cetuximab in therapy of metastatic colorectal cancer: a system evaluation].
Hou SH; Liang XB; Bai WQ; Yang J; Yan D; Zhang X; Wang LC
Zhonghua Yi Xue Za Zhi; 2009 May; 89(20):1387-90. PubMed ID: 19671328
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab: new drug. Metastatic colorectal cancer: an inappropriate evaluation.
Prescrire Int; 2005 Dec; 14(80):215-7. PubMed ID: 16400742
[TBL] [Abstract][Full Text] [Related]
5. New systemic frontline treatment for metastatic colorectal carcinoma.
Braun AH; Achterrath W; Wilke H; Vanhoefer U; Harstrick A; Preusser P
Cancer; 2004 Apr; 100(8):1558-77. PubMed ID: 15073842
[TBL] [Abstract][Full Text] [Related]
6. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD).
Sastre J; Aranda E; Grávalos C; Massutí B; Varella-Garcia M; Rivera F; Soler G; Carrato A; Manzano JL; Díaz-Rubio E; Hidalgo M
Crit Rev Oncol Hematol; 2011 Jan; 77(1):78-84. PubMed ID: 20042346
[TBL] [Abstract][Full Text] [Related]
7. EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients.
Li YH; Wang F; Shen L; Deng YM; Shao Q; Feng F; An X; Wang FH; Wang ZQ; Xu RH; Shao JY
Clin Cancer Res; 2011 Jan; 17(2):382-90. PubMed ID: 20884623
[TBL] [Abstract][Full Text] [Related]
8. Third-line therapy for metastatic colorectal cancer.
Gundgaard MG; Soerensen JB; Ehrnrooth E
Cancer Chemother Pharmacol; 2008 Jan; 61(1):1-13. PubMed ID: 17786445
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
10. Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer.
Woo J; Palmisiano N; Tester W; Leighton JC
Cancer; 2013 Jun; 119(11):1941-50. PubMed ID: 23504768
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab-based therapy vs noncetuximab therapy in advanced or metastatic colorectal cancer: a meta-analysis of seven randomized controlled trials.
Liu L; Cao Y; Tan A; Liao C; Mo Z; Gao F
Colorectal Dis; 2010 May; 12(5):399-406. PubMed ID: 19508512
[TBL] [Abstract][Full Text] [Related]
12. The role of cetuximab in the therapy of previously treated advanced colorectal cancer.
Chong G; Cunningham D
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S55-8. PubMed ID: 16399433
[TBL] [Abstract][Full Text] [Related]
13. [Study into the use of cetuximab in metastatic colorectal cancer in a third level hospital].
Marín Pozo JF; Oya Alvarez de Morales B; Caba Porras I; Aranda García J
Farm Hosp; 2009; 33(2):72-9. PubMed ID: 19480794
[TBL] [Abstract][Full Text] [Related]
14. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
Yang H; Yu AP; Wu EQ; Yim YM; Yu E
J Med Econ; 2011; 14(5):542-52. PubMed ID: 21728912
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab in the treatment of colorectal cancer.
Ciardiello F; De Vita F; Orditura M; Comunale D; Galizia G
Future Oncol; 2005 Apr; 1(2):173-81. PubMed ID: 16555987
[TBL] [Abstract][Full Text] [Related]
16. Response to reintroduction of cetuximab in 5 patients with advanced, chemotherapy-resistant, colorectal cancer without progressive disease following first-line therapy with a cetuximab-containing regimen.
Kaechele V; von Wichert G; Adler G; Seufferlein T
Oncology; 2008; 74(3-4):123-6. PubMed ID: 18708729
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials.
Liu L; Cao Y; Tan A; Liao C; Gao F
Cancer Chemother Pharmacol; 2010 Apr; 65(5):849-61. PubMed ID: 19680654
[TBL] [Abstract][Full Text] [Related]
18. Update on novel strategies to optimize cetuximab therapy in patients with metastatic colorectal cancer.
Macarulla T; Ramos FJ; Elez E; Capdevila J; Peralta S; Tabernero J
Clin Colorectal Cancer; 2008 Sep; 7(5):300-8. PubMed ID: 18794061
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab therapy in the treatment of metastatic colorectal cancer: the future frontier?
Gomez D; De Rosa A; Addison A; Brooks A; Malik HZ; Cameron IC
Int J Surg; 2013; 11(7):507-13. PubMed ID: 23660586
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.
Adams R; Meade A; Wasan H; Griffiths G; Maughan T
Expert Rev Anticancer Ther; 2008 Aug; 8(8):1237-45. PubMed ID: 18699762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]